RxDoctor Payments Data

Shannon Shellenhamer, PA

Physician Assistant · Ashland, VANPI 1013352624

Payments from drug & device makers

$3,264in general payments, 2019–2025

Across 180 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$445
  • Novo Nordisk$373
  • Amgen$295
  • Lilly USA, LLC$290
  • Esperion Therapeutics, Inc.$152
  • plus $689 from 14 others

What the payments were for

  • Food & beverage$3,264100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,264 in reported general payments places this provider in the 85th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$41,205
Medicare patients
179
Services billed
535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$34,023
JardianceEmpagliflozin31$30,448
FarxigaDapagliflozin Propanediol33$29,302
MounjaroTirzepatide15$22,925
Repatha SyringeEvolocumab14$15,018
XareltoRivaroxaban13$11,353
Atorvastatin Calcium116$1,033
Albuterol Sulfate HfaAlbuterol Sulfate42$976
Duloxetine Hcl30$912
Tolterodine Tartrate12$835
Gabapentin55$829
Rosuvastatin Calcium90$710
Clobetasol Propionate13$602
Amlodipine Besylate124$601
Losartan Potassium95$598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$373$34,02334 claims
Boehringer IngelheimJardiance$60$30,44831 claims
AstraZenecaFarxiga$1,020$29,30233 claims
Lilly USA, LLCMounjaro$290$22,92515 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$55570 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Ashland

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →